Abstract
Internal tandem duplications (ITD) and D835 point mutations of the receptor tyrosine kinase (RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML). These genetic aberrations may lead to the constitutive activation of the receptor, thus providing the molecular basis for a persisting growth stimulus. We have screened 69 AML-derived cell lines for FLT3 mutations. Four of these cell lines showed ITD of the FLT3 gene, none carried a D835 point mutation. Two cell lines (MUTZ-11 and MV4-11) expressed exclusively the mutated allele, the other two cell lines (MOLM-13 and PL-21) displayed a mutated and the wild-type version of the gene. Although mutationally activated FLT3 is supposed to substitute for the stimulatory signal of a growth factor, one of these cell lines (MUTZ-11) was strictly cytokine-dependent. FLT3 transcripts were found in all four cell lines, but the constitutively phosphorylated receptor protein was clearly detectable only in cell line MV4-11, possibly explaining why MUTZ-11 cells were growth-factor dependent. Thus, not all FLT3 ITD-positive cells express high levels of the active receptor protein, a finding that might be of relevance for a possible future application of a kinase inhibitor as therapeutic agent. It had been described that STAT-5 phosphorylation was part of the FLT3 signalling chain and that STAT-5 molecules were constitutively phosphorylated in FLT3 ITD-positive cells. Although we observed the constitutive phosphorylation of STAT-5 molecules in FLT3-mutant cells, FLT3 ligand (FL) did not induce STAT-5 phosphorylation in FLT3 wild-type cells. These results suggest that the signalling mechanisms of the mutated FL receptor differ at least to some extent from those conferred by wild-type FLT3. In conclusion, (1) not all cells with FLT3 ITD express significant amounts of the mutated receptor protein; (2) signals downstream from wild-type and mutant FLT3 receptors are not 100% idential; and (3) MV4-11 represents a model cell line for FLT3 ITD signalling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Birg, F, Courcoul, M, Rosnet, O, Bardin, F, Pebusque, MJ, Marchetto, S, Tabilio, A, Mannoni, P & Birnbaum, D. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, (1992). 80, 2584–2593.
Carow, CE, Levenstein, M, Kaufmann, SH, Chen, J, Amin, S, Rockwell, P, Witte, L, Borowitz, MJ, Civin, CI & Small, D. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/FLK2) in human leukemias. Blood, (1996). 87, 1089–1096.
Rosnet, O, Bühring, HJ, Marchetto, S, Rappold, I, Lavagna, C, Sainty, D, Arnoulet, C, Chabannon, C, Kanz, L, Hannum, C & Birnbaum, D Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia, (1996). 10, 238–248.
Meierhoff, G, Dehmel, U, Gruss, HJ, Rosnet, O, Birnbaum, D, Quentmeier, H, Dirks, W & Drexler, HG Expression of FLT3 receptor and FLT3-ligand in human leukemia–lymphoma cell lines. Leukemia, (1995). 9, 1368–1372.
Dehmel, U, Zaborski, M, Meierhoff, G, Rosnet, O, Birnbaum, D, Ludwig, WD, Quentmeier, H & Drexler, HG Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia, (1996). 10, 261–270.
Stacchini, A, Fubini, L, Severino, A, Sanavio, F, Aglietta, M & Piacibello, W Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia, (1996). 10, 1584–1591.
Nakao, M, Yokota, S, Iwai, T, Kaneko, H, Horiike, S, Kashima, K, Sonoda, Y, Fujimoto, T & Misawa, S Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, (1996). 10, 1911–1918.
Yokota, S, Kiyoi, H, Nakao, M, Iwai, T, Misawa, S, Okuda, T, Sonoda, Y, Abe, T, Kahsima, K, Matsuo, Y & Naoe, T Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, (1997). 11, 1605–1609.
Kiyoi, H, Naoe, T, Nakano, Y, Yokota, S, Minami, S, Miyawaki, S, Asou, N, Kuriyama, K, Jinnai, I, Shimazaki, C, Akiyama, H, Saito, K, Oh, H, Motoji, T, Omoto, E, Saito, H, Ohno, R & Ueda, R Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, (1999). 93, 3074–3080.
Kiyoi, H, Naoe, T, Yokota, S, Nakao, M, Minami, S, Kuriyama, K, Takeshita, A, Saito, K, Hasegawa, S, Shimodaira, S, Tamura, J, Shimazaki, C, Matsue, K, Kobayashi, H, Arima, N, Suziki, R, Morishita, H, Saito, H, Ueda, R & Ohno, R, the Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia, (1997). 11, 1447–1452.
Meshinchi, S, Woods, WG, Stirewalt, DL, Sweetser, DA, Buckley, JD, Tjoa, TK, Bernstein, ID & Radich, JP Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, (2001). 97, 89–94.
Rombouts, WJC, Blokland, I, Löwenberg, B & Ploemacher, RE Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia, (2000). 14, 675–683.
Kiyoi, H, Towatari, M, Yokota, S, Hamaguchi, M, Ohno, R, Saito, H & Naoe, T Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia, (1998). 12, 1333–1337.
Hayakawa, F, Towatari, M, Kiyoi, H, Tanimoto, M, Kitamura, T, Saito, H & Naoe, T Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, (2000). 19, 624–631.
Mizuki, M, Fenski, R, Halfter, H, Matsumura, I, Schmidt, R, Müller, C, Grüning, W, Kratz-Albers, K, Serve, S, Steur, C, Büchner, T, Kienast, J, Kanakura, Y, Berdel, WE & Serve, H Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, (2000). 96, 3907–3914.
Tse, KF, Novelli, E, Civin, CI, Bohmer, FD & Small, D Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia, (2001). 15, 1001–1010.
Levis, M, Tse, KF, Smith, BD, Garrett, E & Small, D A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood, (2001). 98, 885–887.
Yamamoto, Y, Kiyoi, H, Nakano, Y, Suzuki, R, Kodera, Y, Miyawaki, S, Asou, N, Kuriyama, K, Yagasaki, F, Shimazaki, C, Akiyama, H, Saito, K, Nishimura, M, Motoji, T, Shinagawa, K, Takeshita, A, Saito, H, Ueda, R, Ohno, R & Naoe, T Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, (2001). 97, 2434–2439.
Abu-Duhier, FM, Goodeve, AC, Wilson, GA, Care, RS, Peake, IR & Reilly, JT Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol, (2001). 113, 983–988.
Serve, H, Flesch, K, Serve, S, Fenski, R & Berdel, WE Expression and function of Flt3/flk2 in human tumor cell lines. Int J Oncol, (1999). 14, 765–770.
Drexler, HG, Dirks, W, MacLeod, RAF, Quentmeier, H, Steube, KG & Uphoff, CC DSMZ Catalogue of Human and Animal Cell Lines, 8th edn, DSMZ: Braunschweig, Germany (2001).
Drexler, HG The Leukemia–Lymphoma Cell Line Factsbook, Academic Press: San Diego, CA (2000).
Abu-Duhier, FM, Goodeve, AC, Wilson, GA, Care, RS, Peake, IR & Reilly, JT Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol, (2001). 113, 1076–1089.
Dirks, W, MacLeod, RAF, Jäger, K, Milch, H & Drexler, HG First searchable database for DNA profiles of human cell lines: sequential use of fingerprint techniques for authentication. Cell Mol Biol, (1999). 45, 841–853.
Zhang, S, Fukuda, S, Lee, Y, Hangoc, G, Cooper, S, Spolski, R, Leonard, WJ & Broxmeyer, HE Essential role of signal transducer and activator of transcripion (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med, (2000). 192, 719–728.
Birkenkamp, KU, Geugien, M, Lemmink, HH, Kruijer, W & Vellenga, E Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia, (2001). 15, 1923–1931.
Tse, KF, Mukherjee, G & Small, D Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia, (2000). 14, 1766–1776.
Srinivasa, SP & Doshi, PD Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia, (2002). 16, 244–253.
Beslu, N, LaRose, J, Casteran, N, Birnbaum, D, Lecocq, E, Dubreuil, P & Rottapel, R Phosphatidylinositol-3′ kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase. J Biol Chem, (1996). 271, 20075–20081.
Reilly, JT Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol, (2002). 116, 744–757.
Fenski, R, Flesch, K, Serve, S, Mizuki, M, Oelmann, E, Kratz-Albers, K, Kienast, J, Leo, R, Schwartz, S, Berdel, WE & Serve, H Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol, (2000). 108, 322–330.
Whitman, SP, Archer, KJ, Feng, L, Baldus, C, Becknell, B, Carlson, BD, Carroll, AJ, Mrozek, K, Vardiman, JW, George, SL, Kolitz, JE, Larson, RA, Bloomfield, CD & Caligiuri, MA Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res, (2001). 61, 7233–7239.
Acknowledgements
We thank Mrs Ina Kramer (DSMZ) for sequencing FLT3 ITD.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quentmeier, H., Reinhardt, J., Zaborski, M. et al. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17, 120–124 (2003). https://doi.org/10.1038/sj.leu.2402740
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402740
Keywords
This article is cited by
-
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Nature Chemical Biology (2023)
-
Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
BMC Cancer (2022)
-
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
Journal of Experimental & Clinical Cancer Research (2022)
-
FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells
Scientific Reports (2021)
-
CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells
British Journal of Cancer (2021)